

Project Title: Establishment of an International Diffuse Intrinsic Pontine Glioma (DIPG) Registry

Section 1: Contact Information

a. Investigators:

Primary Investigator:

Name and title:	Maryam Fouladi, MD, MSc, Professor, Medical Director of Neuro-oncology
Address:	Cincinnati Children's Hospital Medical Center 3333 Burnet Avenue, MLC 7015 Cincinnati, OH 45229
Phone Number:	513-803-0721
Email:	Maryam Foualdi@cchmc.org
Signature:	

Co-Primary Investigator: Dannis G. van Vuurden, Pediatric Oncologist / Hematologist, Department of Pediatrics, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Tel: +31 20 44 42420 / Tracer *7212, dg.vanvuurden@vumc.nl

Designated Official: J.C. Klarenbeek, Manager business operations Division III, VU University Medical Center, de Boelelaan 1117, 1007 MB Amsterdam, The Netherlands. Tel: +31-20-444-3231 Fax: +31-20-444-4975, e-mail: jc.klarenbeek@vumc.nl

Co-Primary Investigator: Katherine Warren, Director of Neuro-Oncology, National Institute of Health, National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, MSC 1104, 10 CRC 1W-3750, Bethesda, MD, 20892-1104, Tel: 301-435-4683, warrenk@mail.nih.gov

Designated Official: Jonathan Wiest, Ph.D., National Cancer Institute, 31 Center Drive, Bethesda, MD, 20892-2440, Tel: 301-451-9638m wiestj@mail.nih.gov

Co-Primary Investigator: Sharon Savage, Investigator, National Institute of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, 6120 Executive Boulevard, MSC 7242, Bethesda, MD, 20892-7335, Tel: 301-496-5785, savagesh@mail.nih.gov

Designated Official: Jonathan Wiest, Ph.D., National Cancer Institute, 31 Center Drive, Bethesda, MD, 20892-2440, Tel: 301-451-9638m wiestj@mail.nih.gov

Co-Primary Investigator: Cynthia Hawkins, Neuropathologist; Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-5938, cynthia.hawkins@sickkids.ca

Designated Official: Dr. Janet Rossant, Director, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-6577, janet.rossant@sickkids.ca

Co-Primary Investigator: Eric Bouffet, Director of Neuro-oncology; Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-7457, eric.bouffet@sickkids.ca

Designated Official: Dr. Janet Rossant, Director, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-6577, janet.rossant@sickkids.ca

Co-Primary Investigator: Ute Bartels, Pediatric Neuro-oncologist; Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-8889, ute.bartels@sickkids.ca

Designated Official: Dr. Janet Rossant, Director, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada; M5G 1X8; Tel: 416 813-6577, janet.rossant@sickkids.ca

Co-Primary Investigator: Darren Hargrave, Consultant Pediatric Oncologist, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, WC1N 3JH, United Kingdom, Tel: +44 020 7405 9200, darren.hargrave@nhs.net

Designated Official: Darren Hargrave, Consultant Pediatric Oncologist, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, WC1N 3JH, United Kingdom, Tel: +44 020 7405 9200, darren.hargrave@nhs.net

Co-Primary Investigator: Jacques Grill, Pediatric oncologist; Gustave Roussy Institute; 39 Bis Rue Camille Desmoulins, 94800 Villejuif, France. Tel: 01 45 21 6119, jacquesgrill@yahoo.fr

Designated Official: Jacques Grill, Pediatric oncologist; Gustave Roussy Institute; 39 Bis Rue Camille Desmoulins, 94800 Villejuif, France. Tel: 01 45 21 6119, jacquesgrill@yahoo.fr

Co-Primary Investigator: Chris Jones, PhD FRCPath, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom, Tel: +44 0 20 8722 4416, chris.jones@icr.ac.uk

Designated Official: David Begg, Institute of Cancer Research, 123 Old Brompton Road London SW7 3RP, Tel +44 (0)20 7352 5195, david.begg@icr.ac.uk

Co-Primary Investigator: Lili Miles, MD, neuropathologist, Cincinnati Children's Hospital Medical Center, , 3333 Burnet Ave, Cincinnati, OH 45229. Tel: 513-636-2785, lili.miles@cchmc.org

Designated Official: Tana Housh, Manager of Sponsored Programs, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, tel 513-636-1363, sponsoredprograms@cchmc.org

Co- Primary Investigator: James Leach, Pediatric Neuroradiologist, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, Tel: 513-636-7591, James.Leach@cchmc.org

Designated Official: Tana Housh, Manager of Sponsored Programs, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, tel 513-636-1363, sponsoredprograms@cchmc.org

Co- Primary Investigator: Blaise Jones, Pediatric Neuroradiologist, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, Tel: 513-636-8574, blaise.jones@cchmc.org

Designated Official: Tana Housh, Manager of Sponsored Programs, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, tel 513-636-1363, sponsoredprograms@cchmc.org

Co- Primary Investigator: Dawn Saunders, Pediatric Neuroradiologist, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, WC1N 3JH, United Kingdom, Tel: +44 020 7405 9200, saundd@gosh.nhs.uk

Designated Official: Dawn Saunders, Pediatric Neuroradiologist, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, WC1N 3JH, United Kingdom, Tel: +44 020 7405 9200, saundd@gosh.nhs.uk

Co- Investigator: Pieter Wesseling, MD, PhD, Neuropathologist, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands, Tel: 0031 24 361 4323, p.wesseling@pathol.umcn.nl

Designated Official: J.C. Klarenbeek, Manager business operations Division III, VU University Medical Center, de Boelelaan 1117, 1007 MB Amsterdam, The Netherlands. Tel: +31-20-444-3231 Fax: +31-20-444-4975, e-mail: jc.klarenbeek@vumc.nl

Co- Investigator: Thomas Jacques, University of College London, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, Tel: 020 78298895, t.jacques@ich.ucl.ac.uk

Designated Official: Thomas Jacques, University of College London, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, Tel: 020 78298895, t.jacques@ich.ucl.ac.uk

Co- Investigator: Pascale Varlet, Hopital Sainte Anne, 1 Rue Cabanis, 75014 Paris, Tel: 01 45 65 80 00, p.varlet@ch-sainte-anne.fr

Designated Official: Pascale Varlet, Hopital Sainte Anne, 1 Rue Cabanis, 75014 Paris, Tel: 01 45 65 80 00, p.varlet@ch-sainte-anne.fr

Co-Primary Investigator: Mi-OK Kim, PhD, statistician, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Tel: 513-636-1895. MiOk.kim@cchmc.org

Designated Official: Tana Housh, Manager of Sponsored Programs, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, tel 513-636-1363, sponsoredprograms@cchmc.org

Collaborators

Suzanne Baker, PhD, Developmental Neurobiologist, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-3678, Tel: 901-595-2254, suzanne.baker@stjude.org

Consultants:

Gilbert Vezina, MD, Professor of Radiology and Pediatrics, Children's National Medical Center, Center for Neuroscience Research, 111 Michigan Avenue NW, Washington, D.C. 20010-2970, Tel: 202-476-2389, gvezina@childrensnational.org

Tina Young Poussaint, MD, Professor of Radiology, Harvard Medical School, Director, PBTC Neuroimaging Center, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, Tel: 617 355-6450,

tinayoung.poussaint@childrens.harvard.edu

b. Institutional Authority

Name and title:	Tana Housh, Manager of Sponsored Programs
Address:	Cincinnati Children's Hospital Medical Center 3333 Burnet Avenue Cincinnati, OH 45229
Phone Number:	513-636-1363
Email:	Sponsoredprograms@cchmc.org
Signature:	

Section 2: Executive Summary

Brainstem gliomas account for up to 20% of all CNS tumors in children with a median age at presentation of 6-7 years.¹ Diffuse intrinsic pontine gliomas (DIPG) comprise 80% of all brainstem gliomas. In North America and Europe, approximately 300 children develop brainstem gliomas per year.² Prognosis for patients with DIPGs remains dismal with a median survival of less than 1 year. Although radiotherapy does improve neurological function and survival by 2-3 months, no effective chemotherapeutic regimens are currently available.^{1,2} Achieving cure for all children with DIPG remains a major goal of pediatric neuro-oncology. In this application, **we propose the establishment of an International Diffuse Intrinsic Pontine Glioma Registry to provide a comprehensive database of clinical, radiologic and pathologic data linked to a bioinformatics repository of molecular data of patients.** The specific aims include: a) To recruit patients diagnosed with DIPG in the International DIPG Registry; b) To provide a repository of clinical and demographic, radiological, pathologic data for patients with DIPG enrolled on the registry and maintain annual follow-up on all cases; c) To develop a bioinformatics repository of existing molecular data on DIPGs that can be linked to patient information in the registry; d) To establish collaborations among investigators for hypothesis-driven research studies through the registry that will ultimately lead to better classification and more effective treatment of patients with DIPG. The first two projects proposed for specific aim 4 are a comprehensive study of long-term DIPG survivors based on data (clinical, radiographic, molecular and pathologic) captured in the registry, as well as an epidemiological study to assess the incidence patterns of DIPG in North America. **Our long-term goal is to establish and maintain a highly collaborative, international, hypothesis-driven research infrastructure that can support a wide spectrum of interdisciplinary and translational projects in DIPGs for all investigators.** The data collected form a research continuum from basic biology to clinical practice that will ultimately address our primary goals of a) understanding the biology of DIPGs, b) developing more effective therapies and c) developing new approaches to diagnosis, response assessment and multidisciplinary treatment and follow-up that will improve patient outcome.